trial · primary record
Mirdametinib
LGCMN
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2032-01-04 |
| Primary endpoint | Determine whether treatment with mirdametinib results in objective decreases in the largest diameter of LGCMN |
| Registry ID | NCT07891286 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:13.141Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07891286
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- MIRDAMETINIB · approval
- Mirdametinib · compound